New data from DR.CI:LABO™ at IMCAS Asia 2025 reinforces leadership in adjunctive clinical skincare for daily and post-IPL care for Asian skin

SINGAPORE, June 10, 2025 /PRNewswire/ -- DR.CI:LABO™, Japan's clinic-born leading derma-cosmetics brand, unveiled new findings at IMCAS Asia 2025, reaffirming its position as the go-to skincare brand for Asian skin. The data demonstrated the efficacy of VC100 Essence Lotion EX and 377VC Radiance Serum in improving skin hydration, elasticity, and pigmentation when used daily and post-IPL[1] care.

"At IMCAS Asia 2025, we're proud to present new clinical evidence that reflects the needs of today's consumers and supports their aesthetic and skincare choices. Our role is to provide safe, effective skincare solutions like VC100 Essence Lotion EX and 377VC Radiance Serum that can be used as daily skincare, enhance recovery and extend results of aesthetic treatments," said Dr. Sheila Chua, Board-Certified Dermatologist and Head of Medical & Safety Sciences, Skin Health & Beauty, Kenvue Asia Pacific.

VC100 Essence Lotion EX: Now with clinically proven efficacy for regular daily and post-IPL care

At IMCAS Asia 2025, DR.CI:LABO™ presented new clinical data highlighting the benefits of twice-daily use of VC100 Essence Lotion EX over eight weeks on Asian skin. Powered by 100 trillion Micro-High Penetrating APPS Vitamin C, the formulation delivered visible improvements across key skin indicators including hydration, elasticity and gloss by 21.6%, 14.6%, 8.7% respectively, and reduction in hyperpigmentation by 5.9%.[2] The study also showed a significant boost in the synthesis of five different types of collagen, increased collagen density, and skin firmness.

This builds on findings presented at the American Academy of Dermatology 2025, where twice daily use of VC100 Essence Lotion EX and Emulsion over a span of eight weeks showed a similar trend of improvement to IPL.[3],[4] When used in combination with IPL, hydration and elasticity improved by 25.4% and 15.5% respectively, compared to 20.8% and 10.9% with IPL alone, and hyperpigmentation reduction accelerated, with visible improvement by Week Two.

377VC Radiance Serum: A proven brightening adjunct for IPL-treated skin

DR.CI:LABO™ also shared clinical data on 377VC Radiance Serum at IMCAS. In a five-week, randomized controlled trial, participants who used the serum daily post-IPL showed a 31.88% reduction in Melasma Area and Severity Index and a 22.13% reduction in hyperpigmentation, compared to 8.92% and 8.52% in participants that only received IPL.[5] Skin image analysis further indicates reversing and reduced risk of potential re-darkening after IPL. The serum was well tolerated on treated skin in favorable state, supporting its use in post-IPL care and reaffirming its safety profile.[5]

Findings presented at IMCAS from asurvey of 844 dermatologists in China validated DR.CI:LABO™'s clinical approach and reinforces its clinical credibility:

• 83% agreed that 377VC Radiance Serum reduces melanin synthesis and improves skin brightness,
• Over 75% believed it enhances post-IPL outcomes and helps prevent post-inflammatory hyperpigmentation, and
• 99% acknowledged growing patient demand for adjunctive clinical skincare.[6]

For a detailed overview of products and posters exhibited, refer to the Data and Product Fact Sheet. For more information, visit the DR.CI:LABO™ website.

About DR.CI:LABO™

Since 1999, DR.CI:LABO™ has pioneered the advancement of skincare solutions in collagen health. For over 25 years, DR.CI:LABO™ is dedicated to providing skincare solutions that unlock the potential for beauty within every skin and democratize access to clinic level treatments for all.

[1] Intense Pulsed Laser

[2] Taichi Nishizawa et. al., "Ex-vivo and Clinical Study of an Amphiphilic Vitamin C Derivative to Enhance Dermal Collagen and Skin Gloss", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand

[3] Frequency of IPL treatment administered: 3 times every 2 weeks, over 8 weeks (IPL output: 10-13J, about 100 shots).

[4] Masahiko Ando et. al., Clinical efficacy assessment of skin care formulations containing trisodium ascorbyl6-palmitate 2-phosphate (APPS) for pre-aging skin, Poster number 61671, American Academy of Dermatology Annual Meeting, 7-11 March 2025, Orlando, Florida

[5] Yueying Fu et. al., "Clinical Safety and Efficacy of a Novel Topical Phenylethyl Resorcinol Formulation for Intense Pulsed Light Adjunctive Usage for Solar Lentigo and Melasma skin", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand

[6] Joleen Goh et. al., "Knowledge, Attitude, and Practice Towards the Adjunctive Perioperative Use of Phenylethyl Resorcinol with Aesthetic Treatments", IMACS Asia 2025, 6-8 June 2025, Bangkok, Thailand